Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.50 |
| ▸ | PDE9A | O76083 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311007 | 0.88 | OGA (0.53) | CHRNB2CHRNA4PDE9AOGACHRNB4 | |
| SCHEMBL20147421 | 0.85 | OGA (0.57) | CHRNB2CHRNA4OGACHRNB4CHRNA3 | |
| SCHEMBL12819481 | 0.82 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3GRIN1 | |
| SCHEMBL24188514 | 0.80 | HRH3 (0.42) | GRIN1GRIN2B | |
| SCHEMBL12030786 | 0.80 | SLC6A2 (0.51) | PDE9A | |
| SCHEMBL20069120 | 0.79 | CHRNB2 (0.54) | CHRNB2CHRNA4GRIN1GRIN2BHTR2A | |
| SCHEMBL13819925 | 0.79 | SPR (0.47) | CHRNB2CHRNA4PDE9ACHRNB4CHRNA3 | |
| SCHEMBL25839756 | 0.79 | CHRNB2 (0.45) | CHRNB2CHRNA4PDE9AOGACHRNB4 | |
| SCHEMBL14805856 | 0.78 | CHRNB2 (0.50) | CHRNB2CHRNA4PDE9ACHRNB4CHRNA3 | |
| SCHEMBL6123545 | 0.76 | HRH3 (0.51) | CHRNB2CHRNA4GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-02 | — | — | US | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220017509-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-11008335-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200181166-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-06-11 | — | — | US | disclosed |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CHRNB2 2262/4885CHRNA4 1854/4885PDE9A 1154/4885 |
| US-11008335-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM2 | CHRNB2 19/4885CHRNA4 6/4885PDE9A 348/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CHRNB2 2262/4885CHRNA4 1854/4885PDE9A 1154/4885 |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CHRNB2 2262/4885CHRNA4 1854/4885PDE9A 1154/4885 |
| US-20200181166-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM2 | CHRNB2 19/4885CHRNA4 6/4885PDE9A 348/4885 |
| US-11858925-B2 | GAS41 inhibitors and methods of use thereof | GAS6, HIF1AN, TMEM41B | CHRNB2 4862/4885CHRNA4 4868/4885PDE9A 1072/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CHRNB2 2262/4885CHRNA4 1854/4885PDE9A 1154/4885 |
| US-20220017509-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | GAS6, HIF1AN, TMEM41B | CHRNB2 4862/4885CHRNA4 4868/4885PDE9A 1072/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CHRNB2 2262/4885CHRNA4 1854/4885PDE9A 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.